13 June 2019
BPC-A-31-2019_rev1

Draft agenda

31st meeting of the Biocidal Products Committee (BPC)

25 - 26 June 2019

ECHA Conference Centre, Annankatu 18, Helsinki

Starts on 25 June at 09:30, ends on 26 June at 18:00

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-31-2019_rev1
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-29

BPC-M-29-2019
For agreement

5. – Administrative issues

5.1. Housekeeping issues

For information

5.2. Other administrative issues and report from other Committees

For information

6. – Work programme for BPC

6.1. BPC Work Programme for active substance approval

BPC-31-2019-01
For information

6.2. BPC Work Programme for Union authorisation

BPC-31-2019-02

For information

6.3. Outlook for BPC

BPC-31-2019-03

For information

6.4. Status harmonised classification and labelling for active substances

BPC-31-2019-04

For information

6.5. Status ED assessment for active substances

BPC-31-2019-05

For information

6.6. Follow-up Active Substance Workshop 12-13 February 2019: Note ECHA on requesting additional information during the evaluation phase

BPC-31-2019-09

For information

7. – Applications for approval of active substances*

7.1. Procedural and administrative aspects:

7.1.1. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval

BPC-31-2019-06

For information

7.1.2. Confidentiality claims related to the address of the manufacturer(s) and location of the manufacturing site for the active substance

BPC-31-2019-07

For agreement

7.2. Draft BPC opinion on DBNPA for PT 4

Previous discussion: BPC-26

BPC-31-2019-08A, B, C

For adoption

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

7.3. Revised Assessment Report following the submission of data after active substance approval:

7.3.1. PBO for PT 18

BPC-31-2019-10
For agreement

7.4. Interpreting the definition of relevant impurities

BPC-31-2019-11
For agreement

8. – Union authorisation**

8.1 Update on Union authorisation

For information

8.2 Reporting the assessment of ED properties for the active substance and co-formulants in the BPC opinion

BPC-31-2019-12
For agreement

8.3 Guidance on storage stability – Decision tree

BPC-31-2019-13
For agreement

8.4 Draft BPC opinions on Union authorisation applications for a product family containing octanoic acid

Previous discussion: WG-II-2019

BPC-31-2019-14A, B, C, D
For adoption

8.5 Draft BPC opinions on Union authorisation applications for a product family containing octanoic acid and decanoic acid

Previous discussion: WG-II-2019

BPC-31-2019-15A, B, C, D
For adoption

8.6 Draft BPC opinions on Union authorisation applications for a product family containing permethrin and S-methoprene

Previous discussion: WG-II-2019

BPC-31-2019-16A, B, C, D
For adoption

** For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product familiy (denoted by D).

9. - Any other business

9.1 Consultation Forum sub-group on BPR (BPRS) on risk management measures

BPC-31-2019-17

For discussion

9.2 Risk assessment of the professional user – combination of exposure from product use and dietary intake

BPC-31-2019-18

For discussion

10. - Action points and conclusions

For agreement

Provisional time schedule for the

31st meeting of the Biocidal Products Committee (BPC)

ECHA Conference Centre, Annankatu 18, Helsinki

25 June 2019: starts at 09:30; 26 June 2019 ends at 18:00

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

Tuesday 25 June: morning session

Items 1-5	Opening items and administrative issues	
Item 6	Work programme of the BPC	
	6.1.	BPC Work Programme for active substance approval
	6.2.	BPC Work Programme for Union authorisationl
	6.3.	Outlook for BPC
	6.4.	Status harmonised classification and labelling for active substances
	6.5.	Status ED assessment for active substances
	6.6	Follow-up Active Substance Workshop 12-13 February 2019: Note ECHA on requesting additional information during the evaluation phase
Item 7.1	Procedural and administrative aspects:	
	7.1.1.	Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval
	7.1.2.	Confidentiality claims related to the address of the manufacturer(s) and location of the manufacturing site for the active substance
Item 7.2	Draft BPC opinion on DBNPA for PT 4	

Tuesday 25 June: afternoon session

Item 7.3.	Revised Assessment Report following the submission of data after active substance approval:	
	7.3.1	PBO for PT 18
Item 7.4.	Interpreting the definition of relevant impurities	
Item 9.1	Consultation Forum sub-group on BPR (BPRS) on risk management measures	
Item 9.2	Risk assessment of the professional user – combination of exposure from product use and dietary intake	

Wednesday 26 June: morning session

Item 8.1	Update on Union authorisation
Item 8.2	Reporting the assessment of ED properties for the active substance and co-formulants in the BPC opinion
Item 8.3	Guidance on storage stability – Decision tree
Item 8.4	Draft BPC opinions on Union authorisation applications for a product family containing octanoic acid

Wednesday 26 June: afternoon session

Item 8.5	Draft BPC opinions on Union authorisation applications for a product family containing octanoic acid and decanoic acid
Item 8.6	Draft BPC opinions on Union authorisation applications for a product family containing permethrin and S-methoprene
Item 10	Action points and conclusions

End of meeting

o0o